Physician profile
Thy K Tran
NPI 1588642698
$4,239.34
in general payments reported to CMS, 2019-2025
23 companies · $906 in 2025
The $906 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $791 · 2023: $854 · 2024: $1,237 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.70 |
| Education | $173.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,817.05 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $497.45 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $448.88 | 2021-2025 | Sotyktu |
| Incyte Corporation | $239.01 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $163.32 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $153.22 | 2021-2024 | |
| Genzyme Corporation | $102.95 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.03 | 2022-2024 | Spevigo |
| Amgen INC. | $95.45 | 2022-2024 | Otezla |
| Ucb, INC. | $83.81 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $82.84 | 2021-2025 | |
| Lilly USA, LLC | $82.69 | 2021-2024 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $81.02 | 2021-2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $67.33 | 2022 | |
| Dermavant Sciences, INC. | $59.82 | 2023 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $36.50 | 2025 | Nemluvio |
| Eisai INC. | $23.78 | 2024 | |
| Organogenesis INC. | $20.49 | 2022 | |
| Journey Medical Corporation | $20.48 | 2022 | |
| Arcutis Biotherapeutics, INC. | $18.83 | 2023 | |
| Mayne Pharma Commercial LLC | $17.87 | 2023 | |
| Vyne Pharmaceuticals INC. | $17.39 | 2021 | |
| Mission Pharmacal Company | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.